Labeler
Ipsen Biopharmaceuticals, Inc. NDC Codes
Ipsen Biopharmaceuticals, Inc. lists 17 finished drug products in the FDA NDC Directory under NDC labeler code 15054.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Active ingredients
- Palovarotene, Odevixibat, Lanreotide acetate, Botulinum toxin type a, Elafibranor, Irinotecan hydrochloride, Mecasermin
- NDC labeler codes
- 15054
- Strengths
- Elafibranor 80 mg/1; Odevixibat 200 ug/1; Odevixibat 400 ug/1; Odevixibat 600 ug/1; Odevixibat 1200 ug/1; Palovarotene 1 mg/1; Palovarotene 1.5 mg/1; Palovarotene 2.5 mg/1; Palovarotene 5 mg/1; Palovarotene 10 mg/1; Irinotecan hydrochloride 4.3 mg/mL; Botulinum toxin type a 500 U/1; Botulinum toxin type a 300 U/1; Lanreotide acetate 60 mg/.2mL; Lanreotide acetate 90 mg/.3mL; Lanreotide acetate 120 mg/.5mL; Mecasermin 40 mg/4mL
- Dosage forms
- Capsule, Injection, Capsule, Coated pellets, Injection, Powder, Lyophilized, For solution, Tablet, Film coated, Injection, Powder, For solution, Injection, Solution
- Routes
- Oral, Subcutaneous, Intramuscular, Intravenous
- Drug classes (FDA established)
- Retinoid, Ileal Bile Acid Transporter Inhibitor, Somatostatin Analog, Acetylcholine Release Inhibitor, Neuromuscular Blocker, Peroxisome Proliferator-activated Receptor Agonist, Topoisomerase Inhibitor
- HCPCS / J-code
- None in Med-Code's directory for these products
- Package NDCs
- 19
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Iqirvoelafibranor | Elafibranor 80 mg/1 | Tablet, Film coatedOral | 15054-0080 | 15054-0080-01 | — |
| Bylvayodevixibat | Odevixibat 200 ug/1 | Capsule, Coated pelletsOral | 15054-3301 | 15054-3301-01 | — |
| Bylvayodevixibat | Odevixibat 400 ug/1 | CapsuleOral | 15054-3302 | 15054-3302-01 | — |
| Bylvayodevixibat | Odevixibat 600 ug/1 | Capsule, Coated pelletsOral | 15054-3303 | 15054-3303-01 | — |
| Bylvayodevixibat | Odevixibat 1200 ug/1 | CapsuleOral | 15054-3304 | 15054-3304-01 | — |
| Sohonospalovarotene | Palovarotene 1 mg/1 | CapsuleOral | 15054-0010 | 15054-0010-01 | — |
| Sohonospalovarotene | Palovarotene 1.5 mg/1 | CapsuleOral | 15054-0015 | 15054-0015-01 | — |
| Sohonospalovarotene | Palovarotene 2.5 mg/1 | CapsuleOral | 15054-0025 | 15054-0025-01 | — |
| Sohonospalovarotene | Palovarotene 5 mg/1 | CapsuleOral | 15054-0050 | 15054-0050-01 | — |
| Sohonospalovarotene | Palovarotene 10 mg/1 | CapsuleOral | 15054-0100 | 15054-0100-01 | — |
| Onivydeirinotecan hydrochloride | Irinotecan hydrochloride 4.3 mg/mL | Injection, Powder, For solutionIntravenous | 15054-0043 | 15054-0043-01 | — |
| Dysportbotulinum toxin type a | Botulinum toxin type a 500 U/1 | Injection, Powder, Lyophilized, For solutionIntramuscular | 15054-0500 | 15054-0500-0115054-0500-0215054-0500-09 | — |
| Dysportbotulinum toxin type a | Botulinum toxin type a 300 U/1 | Injection, Powder, Lyophilized, For solutionIntramuscular | 15054-0530 | 15054-0530-06 | — |
| Somatuline Depotlanreotide acetate | Lanreotide acetate 60 mg/.2mL | InjectionSubcutaneous | 15054-1060 | 15054-1060-04 | — |
| Somatuline Depotlanreotide acetate | Lanreotide acetate 90 mg/.3mL | InjectionSubcutaneous | 15054-1090 | 15054-1090-04 | — |
| Somatuline Depotlanreotide acetate | Lanreotide acetate 120 mg/.5mL | InjectionSubcutaneous | 15054-1120 | 15054-1120-04 | — |
| Increlexmecasermin | Mecasermin 40 mg/4mL | Injection, SolutionSubcutaneous | 15054-1040 | 15054-1040-05 | — |
Ipsen Biopharmaceuticals, Inc.: common questions
- What is Ipsen Biopharmaceuticals, Inc.'s NDC labeler code?
- 15054. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Ipsen Biopharmaceuticals, Inc.?
- Med-Code's curated HCPCS directory has no drug-specific code for these products. Drugs dispensed by a pharmacy are billed by NDC. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.